Prahalada S, Hendrickx A G
Teratology. 1983 Apr;27(2):215-22. doi: 10.1002/tera.1420270209.
Thirty timed-mated pregnant rhesus monkeys received Norlestrin (Norethindrone acetate, 2.5 mg, and ethinyl estradiol, 0.05 g per tablet, Parke-Davis) orally at four different dose levels. The dose levels were 5, 10, 25 and 50 mg/day/monkey and the doses were administered during early (days 21-35), late (days 33-46), and throughout (days 21-46) organogenesis, except for the 50-mg-dose-group animals, which were treated only during early organogenesis (days 21-35). All except the animals in the 60-mg-dose group were allowed to go to term (165 days gestation). Pregnancy for the animals in the 50-mg-dose group was terminated by cesarean section on day 50 of gestation and the fetuses were fixed, serially sectioned, and examined histologically. No teratogenicity was observed. However, the prenatal mortality rate (38.5%) was higher for the Norlestrin-treated animals than in the control colony (21%). Eight animals aborted between days 40 and 78 of gestation and two other cases resulted in stillbirths at 139 and 165 days of gestation. There was a higher incidence of abortion (44.4%) in the 25-mg-dose group. Norlestrin treatment during early organogenesis also resulted in a higher abortion rate (37.5%) compared to treatment during late organogenesis (22.2%) abortions). No morphological abnormalities were found in infants observed at birth or in juvenile monkeys which died of natural causes or in those that were sacrificed over a period of two years. No histopathology was observed in the 50-day-old fetuses examined by serial section. Examination of endogenous maternal serum estrogen and progesterone levels in Norlestrin-treated monkeys (25 mg/day, days 21-35) suggested that placental steroidogenesis was not affected; however, the lower levels of estrogen in maternal serum suggested that the ovarian steroidogenesis was affected. Although the precise pathogenesis of this selective embryolethality is not known, several observations in this study suggest a direct generalized embryotoxic effect. Thus, this study for the first time has demonstrated that, while Norlestrin may be embryolethal at 100 times the human contraceptive dose equivalent (25 mg/day) in the rhesus monkey, nevertheless it does not affect the offspring which survive the exposure.
30只经定时交配的怀孕恒河猴按四种不同剂量水平口服诺雷得(醋酸炔诺酮2.5毫克、炔雌醇0.05克/片,帕克-戴维斯公司生产)。剂量水平分别为5、10、25和50毫克/天/猴,给药时间为器官形成早期(第21 - 35天)、晚期(第33 - 46天)以及整个器官形成期(第21 - 46天),但50毫克剂量组动物仅在器官形成早期(第21 - 35天)给药。除60毫克剂量组动物外,其他所有动物均足月分娩(妊娠期165天)。50毫克剂量组动物在妊娠第50天通过剖宫产终止妊娠,胎儿被固定、连续切片并进行组织学检查。未观察到致畸性。然而,接受诺雷得治疗的动物产前死亡率(38.5%)高于对照群体(21%)。8只动物在妊娠第40至78天之间流产,另外两例在妊娠139天和165天出现死产。25毫克剂量组流产发生率较高(44.4%)。与器官形成晚期给药(流产率22.2%)相比,器官形成早期给予诺雷得治疗也导致较高的流产率(37.5%)。在出生时观察到的婴儿、自然死亡的幼年猴子或在两年期间被处死的猴子中均未发现形态学异常。对50日龄胎儿进行连续切片检查未观察到组织病理学变化。对接受诺雷得治疗的猴子(25毫克/天,第21 - 35天)的内源性母体血清雌激素和孕酮水平进行检测表明,胎盘类固醇生成未受影响;然而,母体血清中雌激素水平较低表明卵巢类固醇生成受到影响。尽管这种选择性胚胎致死的确切发病机制尚不清楚,但本研究中的一些观察结果提示存在直接的全身性胚胎毒性作用。因此,本研究首次表明,虽然诺雷得在恒河猴体内以人类避孕剂量等效值的100倍(25毫克/天)给药时可能具有胚胎致死性,但它不会影响在暴露后存活下来的后代。